Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +69.6%
S&P 500 total return (same window) +37.0%
Excess return +32.6%

Annualized: +52.7% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 100.0%

Full portfolio 2 positions

05
Type Streak 8Q trend
MLYS Mineralys Therapeutics, Inc. - Common Stock $213,245,549 92.94% 7,903,838 $-869,422
PHAT Phathom Pharmaceuticals, Inc. - Common Stock $16,208,316 7.06% 1,493,854 $-388,402

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
MLYS Price move only +0 -$869K
PHAT Price move only +0 -$388K